Peter Adams is an expert business builder of technology-based organizations in Life Science, Software, Systems and Services. Peter is a "Growth Catalyst” with strong business relationships across the globe specializing in driving organizations to new levels of performance via 35+ years of world class execution in business development, marketing, and operational leadership within and for Intel, Regis McKenna, McKesson, and other category leaders.
His expertise includes interim executive or consulting assignments and growth strategy engagements, in addition to a series of progressive leadership roles within publicly held, privately owned, government and private equity funded B2B organizations. Throughout his career, he has earned consistent recognition as a growth champion, change agent, business strategist, thought leader — and thrives on addressing the strategic, operational and cultural dynamics necessary to transform companies from market-challenger to market leader positions.
As Senior Health IT Advisor of MaRS Discovery District, Peter specialized in helping start-up companies make all the right moves in the areas of business planning, fund raising, strategic planning, partnerships, brand strategy, and go to market implementation. Immediately prior to this role, he worked as Independent Business Development Consultant in Canada, the UK, US and Europe, home to a number of respected brands including, HP, Intel, Microchip, Mckesson, Motorola, Dixon’s Group, NHS (mobility board member) and the UK Cabinet Office.
Currently, Peter is working helping Canadian, US and UK start-ups with International market entry, fund raising (include venture deck design and pitch coaching) and strategy. He also acts as VP of business development for Vielight Inc. in Toronto and has advised Hamilton Health Sciences on innovation strategy where he holds a position on the research grant evaluation board.
Industry Expertise (10)
Medical Equipment / Supplies / Distribution
Health and Wellness
VC and Private Equity
Advanced Medical Equipment
Information Technology and Services
Areas of Expertise (9)
Healthcare Efficiency and Technology
International Market Development Strategy
Mobile Health Technologies
Senior Health IT Business Advisor – MaRS Discovery District (professional)
MaRS helps create successful global businesses from Canada’s science, technology and social innovation. MaRS provides resources — people, programs, physical facilities, funding and networks — to ensure that critical innovation happens. We stimulate, identify and harness great ideas, nurture their development and guide the transformation of those ideas into reality. We measure our success through the companies that emerge after receiving help from MaRS.
Oxford University (erstwhile Oxford Polytech): HNC (B.Sc. Equiv), Applied Physics
Central School of Speech and Drama, London: Certificate, Acting
Media Appearances (2)
The magic of convergence at MaRS
Advisors with the MaRS life sciences & healthcare practice meet so many talented entrepreneurs—some with brilliant technical skills, some with clinical skills and some with business skills. Rarely do we meet entrepreneurs with all three...
MaRS HIT Forum: Facing the elephants in the room with a fresh approach
I would like to give a short personal history of my experiences leading up to June 7, 2012, when the MaRS Health IT Innovation Forum will launch, because I believe they will help people understand the goals and significance of this event...
Event Appearances (2)
MaRS Health IT Innovation Forum MaRS Discovery District, Toronto
The Effect of eHealth on the Aging Population
Canada 3.0 Conference Stratford, Ontario
Canadian company gives hope to Alzheimer's sufferers with wearable low-level light therapyCision
This could be the first randomized controlled human study that has presented the arrest or reversal in the decline of Alzheimer's Disease. The patients used the "Neuro" for 20 minutes once or twice a week and the "Vielight 810" every day for 25 minutes. The results of this pilot study are significant and strongly suggest that the treatment for people with moderate-severe cognitive impairment can result in significant clinical improvements. People with this level of cognitive impairment are excluded as candidates for pharmaceutical drugs under development or in clinical trials....